You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Local Control of Newly Diagnosed and Distally Recurrent, Low-Volume Brain Metastases With Fixed-Dose (20 Gy) Gamma Knife Radiosurgery

Elliott, Robert E MD*; Rush, Stephen C MD*‡; Morsi, Amr MD*; Mehta, Nisha BA*; Spriet, Jeri BS*; Narayana, Ashwatha MD‡; Donahue, Bernadine MD‡; Parker, Erik C MD*; Golfinos, John G MD*

doi: 10.1227/NEU.0b013e318208f58e
Research-Human-Clinical Studies

BACKGROUND: Metastases to the brain occur in 20% to 30% of patients with cancer and have been identified on autopsy in as many as 50% of patients.

OBJECTIVE: To analyze the efficacy of 20-Gy Gamma Knife radiosurgery (GKR) as initial treatment in patients with 1 to 3 brain metastases ≤ 2 cm in greatest diameter.

METHODS: A retrospective analysis of 114 consecutive adults with Karnofsky performance status ≥ 60 who received GKR for 1 to 3 brain metastases ≤ 2 cm in size was performed. Five patients lacked detailed follow-up and were excluded, leaving 109 for outcome analysis (34 men and 75 women; median age, 61.2 years). All metastases received 20 Gy to the 50% isodose line.

RESULTS: One hundred nine patients underwent treatment of 164 metastases at initial GKR. Twenty-six patients (23.9%) were alive at last follow-up (median time, 29.9 months; range, 6.6 months to 7.8 years). The median overall survival was 13.8 months (range, 1 day to 7.6 years). Among the 52 patients with distant failure, 33 patients received 20 Gy to 95 new lesions. A total of 259 metastases received 20 Gy, and 4 patients lacked imaging follow-up secondary to death before posttreatment imaging. Local failure occurred in 17 of 255 treated lesions (6.7%), yielding an overall local control rate of 93.3%. Actuarial local control at 6, 12, 24, and 36 months was 96%, 93%, 89%, and 88%, respectively. Permanent neurological complications occurred in 3 patients (2.8%).

CONCLUSION: Among patients with 1 to 3 brain metastases ≤ 2 cm in size who have not received whole-brain radiation therapy, GKR with 20 Gy provides high rates of local control with low morbidity and excellent neurological symptom-free survival.

Author Information

Departments of *Neurosurgery and ‡Radiation Oncology, New York University Langone Medical Center, New York, New York

Received, January 2, 2010.

Accepted, July 23, 2010.

Correspondence: John G. Golfinos, MD, Department of Neurosurgery, NYU Langone Medical Center, 530 First Ave, Ste 8R, New York, NY 10016. E-mail:

Copyright © by the Congress of Neurological Surgeons